INTRODUCTION
Both nitric oxide (NO) and prostaglandins (PGs) are relevant mediators in airway physiology and pathology, and their production is regulated by different enzyme isoforms. NO is formed from Larginine by NO synthase (NOS), of which three isoforms have been identified: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) (Ogden et al., 1995) . PG synthesis depends on cyclooxygenase (COX), two main isozymes of which are currently recognised: COX-1, constitutively expressed in different tissues, and COX-2, regarded as an inducible isoform, since an increase in its expression has been associated with inflammatory processes (Simmons and Botting, 2004) .
It is generally believed that the production of NO and PGs by constitutive enzyme isoforms is important for physiological functions, while their formation via inducible isoforms is involved mainly in inflammatory and other pathological responses (Di Rosa et al., 1996) . Increasing evidence suggests a link between NOS and COX pathways (Di Rosa et al., 1996) , but there is no consensus on the functional consequences resulting from their mutual interactions: NO has been reported to regulate the activity of COX enzymes both by enhancing (Salvemini et al., 1993) and inhibiting (Stadler et al., 1993) their expression or modulating their activity (Di Rosa et al., 1996) ; on the other hand, a possible influence of PGs on NOS activity has been proposed and current evidence suggests either inhibition (Marotta et al., 1992; Milano et al., 1995) , stimulation (Milano et al., 1995) or no interaction (Curtis et al., 1996) .
Both NO and COX-derived products influence airway smooth muscle responsiveness to contractile mediators, among which histamine plays a key role in the pathophysiology of allergic responses (Braunstein et al., 1988; Nijkamp et al., 1993) . Nevertheless, the possible therapeutic usefulness of NOS and COX inhibitors in asthmatic hyperreactive airways has not been clearly established.
Advances in the development of selective COX-1 and COX-2 inhibitors have provided useful tools to analyze the contribution of COX pathways to various pathological conditions. However, selective COX-1 or COX-2 inhibitors have shown unclear effects in airways: a therapeutic effect has been reported for COX-2 inhibitors in allergic inflammation (Oguma et al., 2002) or hyperresponsiveness This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on August 22, 2006 as DOI: 10.1124 at ASPET Journals on September 23, 2017 jpet.aspetjournals.org Downloaded from of guinea-pig airways after ozone exposure (Nakano et al., 2000) , while an increase in airway inflammation and muscle hyperresponsiveness has been observed in sensitized mice when treated with COX-1 or COX-2 inhibitors (Peebles et al., 2002) .
The aim of the present study was to determine the influence of COX-1 and COX-2 selective inhibitors, either alone or in combination with a non-selective NOS inhibitor, on in vitro tracheal motor responsiveness to histamine, to examine possible interactions between endogenous NO and COX products relevant to the control of airway smooth muscle reactivity. The study was extended from normal to ovalbumin (OVA)-sensitized and OVA-challenged animals, to identify possible changes in the response to pharmacological treatments resulting from the allergic condition.
This article has not been copyedited and formatted. The final version may differ from this version. Immunohistochemical analysis of COX-1 and COX-2 Tracheo-bronchial tree was removed and placed in phosphate-buffered saline (PBS) maintained at 37°C and oxygenated with carbogen (95% O 2 plus 5% CO 2 ). Tracheal specimens were immediately fixed in cold 4% paraformaldehyde diluted in PBS overnight. Samples were dehydrated with ethanol, treated with xylene and embedded in paraffin at 56°C. Five-micron-thick serial sections were processed for either routine staining by hematoxylin-eosin or immunostaining.
To perform immunohistochemistry, sections were microwaved in citrate buffer and treated with 1% hydrogen peroxide (H 2 O 2 ) in methanol for 30 min, and normal swine serum (1:20) for 20 min at 37°C. The slides were incubated overnight at 4°C with the following polyclonal primary antibodies: rabbit anti-COX-1 (1:80; code no. 160109; Cayman Chemical Company, Michigan, USA); rabbit anti-COX-2 (1:2000; code n° ALX 210711, Alexis Biochemicals, Lausen, Switzerland). Primary immunoglobulins were diluted in PBS with 0.1% bovine serum albumin and 0.1% sodium azide. The immunoprecipitates were detected by an indirect streptavidine-peroxidase method (Dakopatts, Glostrup, Denmark) as previously reported (Bernardini et al., 1999; Virdis et al., 2005) . Briefly, sections were sequentially exposed to biotinylated secondary immunoglobulins and peroxidaselabeled streptavidin complex. The slides were then treated with 3,3'-diaminobenzidine tetrahydrochloride (DAB, 1 mg/ml Tris buffer (Dakopatts Glostrup, Denmark) containing 0.02% H 2 O 2 and counterstained with haematoxylin (1:30). All reactions were carried out at room temperature in a humidified chamber and PBS was used for washes between each step. Negative controls were obtained by omitting primary antibodies or substituting the primary antibody with rabbit preimmune serum. Specificity controls included preadsorption of anti-COX-1 and -COX-2 primary This article has not been copyedited and formatted. The final version may differ from this version. Specimens of six animals from different experimental group were immunostained for COX-1 and COX-2 and then blindly evaluated, using light microscopes, by two investigators (N.B., C.I.) who were unaware of other results. The intensity of immunostaining was ranked as: -(absent), + (weak), ++ (medium), +++ (strong) as previously reported (Fux et al., 2005) .
Antigen sensitization and challenge OVA-sensitization was induced as previously described (Nieri et al., 1992) . Briefly, two consecutive administrations of OVA saline solution (100 mg/kg i.p.
+ 100 mg/kg s.c.) were performed 14-19 days before in vitro experiments. A group of sensitized guinea-pigs were exposed to OVA aerosol (1% in saline) in a box connected to an ultrasonic nebulizer (Artsana, Mod. Project 38080), on days 7, 14, 15 and 16 from sensitization. The aerosol was generated for 10 min, or less if respiratory distress occurred. Respiratory distress was defined as the onset of sneezing, cough and/or indrawing of thoracic wall. Sham-challenged guinea-pigs were exposed to aerosols with saline solution without OVA. Animals were sacrificed for tracheal removal 6 h after the last challenge. Multiple antigen-challenged guinea-pig is a model which reproduces several of the characteristic features of asthma, including bronchial hyperreactivity and inflammation (Samb et al., 2001) . The presence of airway hyperreactivity to histamine was confirmed 6 h after last antigen challenge by preliminary experiments in anaesthetized guinea-pigs, recording pulmonary inflation pressure as an index of airway resistance (data not shown). Assay of prostaglandin E 2 (PGE 2 ) and prostacyclin (PGI 2 ) release PGE 2 and PGI 2 release from tracheal preparations in response to histamine was assessed, both in normal and OVA-sensitized guinea-pigs, to investigate their role in the modulation of tracheal contractile activity by COX-1 and COX-2 isoenzymes. Isolated tracheal rings were incubated using a 24-well plate at 37°C. Each well contained three tracheal rings in 0.5 ml of carbogenated Krebs-Henseleit buffer. Fifteen rings were isolated from each trachea, and therefore five different conditions per preparation could be tested.
PGE 2 or PGI 2 levels were measured after histamine incubation, in the absence or in the presence of SC-560 (10 -6 M) or DFU (10 -6 M), either alone or in combination. The experimental design was the same as that employed for contraction recording, but histamine was applied only at the highest concentration (10 -4 M). The supernatant was collected after 20-min incubation with histamine and stored at -70°C until assay. PGE 2 was assayed as such, while PGI 2 was measured as its stable hydrolysis product 6-keto-PGF 1α . In both cases, an enzyme immunoassay was utilized, in sensitized guinea-pigs; 275.1±27.27 mg tension n=34 for OVA-challenged guinea-pigs). SC-560, DFU or L-NAME did not significantly modify the basal tone of tracheal preparations both in normal and sensitized guinea-pigs, although in a few cases a slight loss of basal tone was observed with COX inhibitors.
Drugs and chemicals
Normal guinea-pigs Histamine (10 -7 -10 -4 M) induced concentration-dependent contractions which were significantly enhanced by COX-1 and COX-2 inhibitors (Fig. 3A,B) . The increment of maximal contraction was 40.0% for SC-560 (10 -6 M) and 32.3% for DFU (10 -6 M). A similar enhancing effect was obtained upon concomitant application of SC-560 and DFU (increment of maximal contraction: 33.0%) (Fig. 3C ). Both COX inhibitors, while enhancing the contractile response to histamine, did not modify its potency, with pD2 values ranging from a minimum of 5.18±0.23 in DFU control group (n=7) to a maximum of 5.54±0.37 in SC-560-treated group (n=8).
The NOS inhibitor L-NAME (10 -4 M) did not influence the tracheal responsiveness to histamine, but suppressed the enhancing effect of SC-560 (Fig. 4A ). In addition, the enhancing action of DFU remained largely unaffected by L-NAME (Fig. 4B) , and the moderate decrease in the effect of DFU, occurring at histamine concentrations below 10 -6 M ( Fig. 3B and 4B ), was likely to reflect the biological variability of experimental settings.
OVA-sensitized guinea-pigs Tracheal preparations from guinea-pigs sensitized to OVA were used to evaluate whether antigen sensitization affects the influence of COX isoforms on airway muscle response to histamine. Under these conditions, the responsiveness to histamine was not significantly affected by SC-560 (10 -6 M), while a significant enhancement was observed with DFU (10 -6 M) (increment of maximal response: 23.6%) (Fig. 5A,B) . L-NAME (10 -4 M) did not significantly influence the control response to histamine, the enhancement induced by DFU, and the contractions evoked by histamine in the presence of SC-560 (Fig. 5C,D) .
OVA-challenged guinea-pigs Although in vivo airway hyperresponsiveness to histamine was observed 6 h after the last aerosol with OVA (data not shown), in vitro experiments did not show any tracheal hyperreactivity to the autacoid, according to findings obtained by Mitchell et al. (2004) in pig bronchi. Fig. 6A shows that the contractile activity evoked by histamine was enhanced by This article has not been copyedited and formatted. The final version may differ from this version. DFU (10 -6 M) (increment of maximal contraction: 37.1%), while it was not modified by SC-560 (10 -6 M). L-NAME did not affect the histamine-induced contraction when assayed alone or in the presence of either COX-1 or COX-2 inhibitor (Fig. 6B ). As already observed for normal animals, in the presence of L-NAME the enhancing action of DFU on the contractile responses to histamine, in tracheal preparations from OVA-challenged guinea-pigs, was not apparent at histamine concentrations lower than 10 -6 M ( fig. 6B ).
Epithelium-denuded trachea from normal and OVA-sensitized guinea-pigs In epithelium-denuded tracheal preparations from normal guinea-pigs, DFU (10 -6 M) did not significantly affect the concentration-response curve to histamine (Fig. 7A ). By contrast, in OVA-sensitized animals, histamine-induced contraction was significantly enhanced by DFU (increment of maximal contraction: 26.4%) (Fig. 7B ). Epithelium removal prevented also the enhancing action of SC-560 (10 -6 M) on histamine-induced contraction in normal animals. In addition, as already observed in preparations with intact epithelium, COX-1 blockade did not modify the responsiveness to histamine following epithelial deprivation of tracheal tissues from OVA-sensitized guinea-pigs (data not shown).
PGE 2 and PGI 2 release A similar basal release of PGE 2 was measured from normal and OVAsensitized guinea-pig trachea (table 2) . Following tracheal stimulation with histamine (10 -4 M) for 20 min, an increase in PGE 2 production was observed in both cases, with a greater increment in preparations from normal animals. SC-560 (10 -6 M) significantly inhibited histamine-induced PGE 2 release when applied to tracheal specimens isolated from normal and OVA-sensitized animals, whereas DFU (10 -6 M) was without effects (table 2) . At variance with PGE 2 , basal PGI 2 release was significantly higher in tracheal tissues from OVA-sensitized guinea-pigs (table 2) . A significant increment of PGI 2 content was detected in the medium after incubation of tracheal specimens with histamine, both in normal and OVA-sensitized animals. Both COX-1 and COX-2 blockade was associated with a decrease in histamine-induced PGI 2 release, the most prominent inhibition being observed upon exposure of tracheal preparations from OVA-sensitized guinea-pigs to DFU ( 
DISCUSSION
The role of COX isozymes in the modulation of airway smooth muscle in healthy subjects is currently debated. Although various authors reported the absence of COX-2 expression in the tracheo-bronchial system of normal guinea-pigs (Amann et al., 2001; Oguma et al., 2002) , the role of COX-2 has been proposed to be relevant in the regulation of tracheal intrinsic tone in this species (Charette et al., 1995) , and a constitutive COX-2 expression has been reported in normal airways (Schlemper et al., 2005) . Our results from normal guinea-pigs, showing that DFU enhances histamine-induced contraction, indicate a functional role for COX-2 isoform which appears to mediate an inhibitory control on airway muscle. It can be excluded that COX-2 activity in normal trachea depends on inducing stimuli linked to surgical manipulation of isolated tissues, since COX-2 expression was clearly revealed by immunohistochemistry in tracheal tissues immediately after excision. Therefore, our data suggest that COX-2 expression in airways does not occur exclusively in inflamed or manipulated tissues and that this isozyme regulates the contractile activity of tracheal smooth muscle under normal conditions.
In the present study, a functional activity, similar to that observed for COX-2, was shown for the COX-1 isoform in normal tissues, where the selective COX-1 inhibitor SC-560 enhanced histamine-induced tracheal contractions. An inhibition of the release of relaxant PGs from the epithelial compartment (Prié et al., 1990 ) is the most likely mechanism explaining tracheal muscle hyperresponsiveness to histamine after blockade of COX activities in normal animals. In support of this view, our experiments showed that immunostaining of both COX isoforms was prevalent in the epithelial layer, and that the DFU-induced enhancement of histamine-induced contraction was abolished in epithelium-deprived tracheal preparations.
At variance with COX inhibitors, L-NAME per se did not modify histamine-induced contraction. In this respect, controversial findings have been reported about the effect of NOS inhibition on airway responsiveness to spasmogens. In guinea-pig trachea with intact epithelial layer, a weak potentiating effect by L-NAME in the proximal, but not distal, portion has been shown (Kloek et al., 2002) . Moreover, the inability of L-NAME to modulate murine tracheal contractile responses to This article has not been copyedited and formatted. The final version may differ from this version. carbachol has been described by Kakuyama et al. (1999) , who observed a L-NAME-induced small increase (about 15%) of maximal response to the cholinergic agonist only when NOS inhibition was tested in the presence of indomethacin. Other authors reported a NO-mediated relaxing effect counterbalancing in vitro tracheal contraction to spasmogens (Nijkamp et al., 1993) , and the use of indomethacin in the organ bath throughout the whole experiment was hypothesised as the cause underlying the L-NAME-induced effect (Kakuyama et al., 1999) . Other factors might be responsible for the conflicting results from different laboratories. For instance, open tracheal preparations (i.e. rings and strips) have been suggested to be insensitive to NO-mediated relaxation, since epithelial-derived NO diffuses away in the medium, thereby decreasing its concentration in proximity of smooth muscle (Folkerts and Nijkamp, 1998) . Moreover, circadian fluctuations of NOS activity have been described in many tissues, including lungs (Tunctan et al., 2002) , and a different metabolism of NO can give rise to formation of reactive molecular species modulating smooth muscle reactivity (Sadeghi-Hashjin et al., 1996) , and even COX activity (Landino et al., 1996) .
Of note, in the present study there was a lack of additivity of the motor enhancing effects exerted by SC-560 and DFU. Moreover, L-NAME, while being ineffective when assayed alone, prevented the stimulant action of SC-560 on histamine-induced contraction, without modifying the potentiating effect of DFU. These findings indicate that both COX isoforms and NOS operate within the same regulatory pathway at level of the tracheal epithelial compartment, and that a complex interplay between COX-1, NOS and COX-2 is likely to exist. In particular, as illustrated schematically in products on NOS activity have been reported in airways (Kakuyana et al., 1999) and other tissues (Marotta et al., 1992; Illiano et al., 1996) , and a COX-2 inhibition by NOS pathway has been previously demonstrated by various authors (Mollace et al., 2005) .
In OVA-sensitized guinea-pigs, the histamine contractile activity was differently modulated by COX inhibitors, since only DFU, but not SC-560, enhanced the autacoid-induced contraction.
These data suggest the occurrence of changes in the respective roles of COX isozymes in the control of airway smooth muscle reactivity, as a consequence of allergic sensitization. The reduced significance of COX-1 isoform in the modulation of histamine-induced contraction, following OVA-sensitization, might depend on the specific localization of this isoform in the epithelial ciliar layer (instead of cytoplasmic compartment as observed for COX-2), which undergoes extensive alteration in sensitized animals, as shown by immunohistochemistry.
With regard to the role played by NOS pathway in sensitized animals, it does not appear to be significant in this setting, since L-NAME did not modify the responsiveness of tracheal preparations to histamine both under control conditions and in the presence of COX-1 or COX-2 blockade. A direct relaxant effect by NO on airway smooth muscle has been excluded also by Larsson et al. (2005) in lung parenchimal strips from sensitized guinea-pigs, where the Authors revealed an indirect protective effect of NO on antigen-induced contraction via inhibition of leukotrienes release from mast cells.
The loss of influence of COX-1 and NOS pathways on COX-2-mediated control of airway muscle responsiveness, taken together with the observation that the enhancing effect of DFU on histamineinduced contractions persisted after epithelium-deprivation of tracheal preparations, suggests that, in antigen-sensitized guinea-pigs, the contractile responsiveness to histamine is modulated by COX-2 at extra-epithelial sites, and that the regulatory network of COX isoforms and NOS at epithelial level looses its functional significance in this setting (Fig. 8B) . In support of this proposal, we obtained immunohistochemical evidence that, following OVA-sensitization, COX-2 expression was markedly increased at subepithelial level, particularly in smooth muscle cells.
This article has not been copyedited and formatted. The final version may differ from this version. (Folkerts and Nijkamp,1998; Carey et al., 2003) . To investigate the role of these prostanoids in the present contractile effects elicited by COX-1 and COX-2 inhibitors, we assayed PGE 2 and PGI 2 release from isolated tracheal preparations. Both in normal and in OVA-sensitized animals, histamineinduced PGE 2 release was not affected by COX-2 blockade, while being inhibited only by SC-560.
However, this observation, indicating COX-1 as the source of PGE 2 release in airways, is consistent with previous findings by Gavett et al. (1999) in mice, where a constitutive expression of both COX-1 and COX-2 in control lung was present, but PGE 2 in bronchoalveolar lavage fluid decreased only in COX-1 knockout animals. When considering PGI 2 , both COX isoforms appear to contribute to its release from tracheal specimens of normal animals, whereas in OVA-sensitized guinea-pigs COX-2 accounted mostly for histamine-induced PGI 2 release, these observations being consistent with immunohistochemical data. These findings, taken together with the results of our experiments on tracheal contractility, suggest that PGI 2 , but not PGE 2 , is responsible for COX-2-mediated modulation of tracheal responsiveness both in normal and OVA-allergic guinea-pigs. In support of such proposal, previous studies have shown that PGI 2 exerts relaxant effects on airway smooth muscle and can be released from tracheal tissues (Prié et al., 1990) . In addition, the COX-2 pathway has been reported to mediate PGI2 production also in smooth muscle cells of extrarespiratory sites, including the vascular system (Schildknecht et al., 2004) .
Tracheal preparations from antigen-challenged guinea-pigs did not display substantially different response patterns with respect to animals subjected only to OVA-sensitization, indicating that, in our experimental model, sensitization alone is able to determine alterations in tracheal responsiveness to COX and NOS inhibitors which persist in the asthma model of antigenchallenged guinea-pig. The absence of a NO-mediated influence on the control of smooth muscle responsiveness in asthmatic airways has been already reported in guinea-pigs as a result of arginase activity up-regulation (Meurs et al., 2002) or nNOS protein down-regulation (Samb et al., 2001 ).
This article has not been copyedited and formatted. The final version may differ from this version. Therefore, our data extend the available evidence indicating a lack of influence by NO on the control of airway smooth muscle responsiveness in multiple antigen-challenged animals, in the presence of COX isoform inhibition.
In conclusion, the main findings obtained in the present work show that: a) both COX-1 and COX-2 isoforms are constitutively expressed in guinea-pig trachea and their inhibition induces tracheal hyperresponsiveness to histamine in normal guinea-pigs, while in antigen-sensitized and challenged animals only COX-2 inhibition is able to evoke such enhancing action; b) in normal guinea-pigs, the NOS pathway mediates a complex interplay between COX-1 and COX-2 at epithelial level,
where COX-1 inhibits NOS, thus preventing the inhibitory action of NOS on COX-2; c) after antigen-sensitization, the epithelial COX-1/NOS/COX-2 network is impaired and COX-2 isoform, upregulated at subepithelial level, particularly in smooth muscle cells, exerts its modulatory function through the release of PGI 2 .
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